This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is Chemed (CHE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CHE) Outperforming Other Medical Stocks This Year?
What Makes Chemed (CHE) a New Buy Stock
by Zacks Equity Research
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.
Chemed (CHE) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 2.22% and -1.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is Chemed (CHE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CHE) Outperforming Other Medical Stocks This Year?
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter performance is likely to reflect growth in its six global business units.
Stryker (SYK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings likely to reflect strong segmental performances by Medsurg and Neurotechnology & Spine.
Why Chemed (CHE) Might Surprise This Earnings Season
by Zacks Equity Research
Chemed (CHE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Juniper (JNPR) This Earnings Season?
by Zacks Equity Research
Juniper's (JNPR) first-quarter 2020 performance is likely to have benefited from changes to its go-to-market structure to better align sales strategies with each of the core customer verticals.
Optical & Display Units to Hurt Corning's (GLW) Q1 Earnings
by Zacks Equity Research
Headwinds in the Optical Communications and Display Technologies business segments are likely to get reflected in Corning's (GLW) first-quarter 2020 results.
The Zacks Analyst Blog Highlights: Limelight Networks, Chemed, Cigna, CURO Group and Huron Consulting Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Limelight Networks, Chemed, Cigna, CURO Group and Huron Consulting Group
Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View
by Zacks Equity Research
Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.
Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical Systems (MMSI) has registered an increase in revenues at both its key operating segments in Q1
ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
ABIOMED's (ABMD) fiscal fourth-quarter performance is likely to reflect growth in Impella product line.
Can Global Industrial Unit Drive Ecolab's (ECL) Q1 Earnings?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in the first quarter.
5 Top Growth Stocks to Buy Ahead of Q1 Earnings This Month
by Nalak Das
Five growth stocks with a favorable Zacks Rank that are set to beat first-quarter earnings estimates this month.
Cerner (CERN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.
DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.
3 Reasons Why Chemed (CHE) Is a Great Growth Stock
by Zacks Equity Research
Chemed (CHE) could produce exceptional returns because of its solid growth attributes.
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.
Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow
by Zacks Equity Research
On coronavirus-led global supply chain disruption, Thermo Fisher (TMO) records a decline in its quarterly Analytical Instruments revenues.
5 Healthcare Stocks Poised to Beat Earnings Estimates in Q1
by Zacks Equity Research
Earnings results of healthcare sector are likely to reflect solid demand for its products and services from aging population and the growing incidence of COVID-19 illness.